SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (1001)6/16/1997 2:50:00 AM
From: Roger Cranwill   of 1762
 
Vector1:
Your point is well taken, and you're probably right-it just depends on timing. By the time Bexxar is approved, C2B8 should be well established in oncology on a par with chemotherapy in efficacy, without the side-effects. At this time, about 2 years down the road, Bexxar comes online-at approximately the same time as Y2B8. I believe IDEC will be able to show that C2B8 used in conjunction with Y2B8 will be on a par in efficacy with the Bexxar, without the amounts of radiation problems presented by Coulter's product; protracted hospitalization till radiation levels are acceptable, and less peripheral tissue damage caused by the radiation. Its a matter of timing, so who's to say? Time will tell...Roger
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News